Germany & Gilead Sciences

Germany: Germany is receiving and treating a US citizen infected with Ebola and quarantining exposed individuals, playing a role in the international medical response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Germany: One of the Western countries that slashed foreign assistance, contributing to Joint United Nations Programme on HIV/AIDS funding loss.

Gilead Sciences: Developed lenacapavir, a highly effective HIV prevention injectable; faces potential revenue impact from generic production in South Africa.

Germany: Reduced HIV funding as part of European cuts, contributing to the overall decline.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

Germany: Treated US citizens evacuated from DRC, including Dr. Brandi Stafford.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Germany: Germany, along with other European governments, has also cut development aid, contributing to the overall reduction in global health funding.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Germany: Germany>>> has received American doctors infected with or exposed to Ebola for treatment and monitoring, serving as a tertiary facility for advanced care.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.

Germany: An American citizen infected with Ebola in the Democratic Republic of the Congo>>> is receiving care in Germany>>>, demonstrating international medical support for severe cases.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.